Drug Discovery Featured Articles & Applications

  1. Manufacturing Process Scale-Up For Phase III
    8/15/2017

    The reality is that several manufacturability problems could be brewing that will rain down during Phase III and cause costly delays, no matter how skilled the product and process may be.

  2. Cold-Chain Fully Automated Assembly And Labeling Of Pre-Filled Syringes
    8/14/2017

    Cold is undeniably the new normal for the biopharmaceutical industry. By 2020, greater than half of bestselling drugs will be cold-chain products, most of which are injectable.

  3. Smaller Biotech Companies and the Single-Source CDMO
    8/14/2017

    A single-source CDMO that manages the end-to-end relationship with pharmaceutical or biopharmaceutical clients can bring many benefits and efficiencies to the development process.

  4. A Single-Vendor CDMO Eases Communication Flow
    8/14/2017

    A single vendor CDMO offers access to a network of experts across several disciplines who can share knowledge about a project as it moves from phase to phaseon a path toward commercial success.

  5. New Resource Saves Drug Developers Time and Money
    8/14/2017

    In the pharmaceutical industry, speed is of the essence. As drug developers face increasing pressure to get formulations to market as efficiently as possible, the CDMO industry is evolving to meet this need.

  6. Bringing The Single-Vendor Approach To The Pharma Industry
    8/14/2017

    As drug developers face increasing pressure to get their products to market as quickly as possible, the CDMO industry is evolving to meet this need by offering end-to-end services.

  7. Solving The OOS Problem With Continuous Manufacturing
    8/13/2017

    With continuous manufacturing, it is possible to monitor product quality continuously, and make adjustments in real time to keep the product in spec.

  8. Why Early Investment In A Scalable Manufacturing Process Is Critical
    8/13/2017

    The failure of drug compounds in mid- to late-stage development is far more common than anyone would like it to be. Only about 30% of compounds successfully transition from Phase II to Phase III.

  9. Characterize Drug Substance Properties Early To Optimize Drug Formulation
    8/13/2017

    Drug substance characterization is critical to drug product formulation but characterization and formulation are often not integrated during drug development. 

  10. Trends and Challenges In Outsourced Oral Solid Dosage Forms
    8/13/2017

    As drug companies have fewer and fewer new compounds entering their R&D pipelines, outsourcing of development and manufacturing activities for oral solid dosage forms and sterile forms is on the rise.